The Impact of Magnesium on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 320 participants.

Also called NCT03840226

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 320 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03840226
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Israel (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03840226. Randomized; single masking; primary purpose treatment. Start 2019-08-25 (actual); primary completion 2026-01-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Impact of Magnesium on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients
Condition
Magnesium Deficiency
Condition
Heart Failure
Intervention (Drug)
Placebo Oral Tablet
Intervention (Drug)
Magnesium Oxide
Lead sponsor
Sheba Medical Center (class: other government)
Collaborator
Naveh Pharma (1996) Ltd. (class: not stated)

Record details

Record id
cardio:ct-nct03840226
Content hash
8f2c900326552b09bc8fc482d44105dee0edd4119f4a951fe7c3f946e0d41713